Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 5Recurrence 3Lymphoma 3Glioblastoma 3Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Glioma 2Brain Neoplasms 2Solid Tumor 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Leukemia 1Gliosarcoma 1Ependymoma 1Disease Progression 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 161Cyclophosphamide 142fludarabine phosphate 89Peripheral Blood Stem Cell Transplantation 81Filgrastim 59Mycophenolic Acid 58Whole-Body Irradiation 53Cyclosporine 53Radiotherapy 52Lenalidomide 47Busulfan 45Tacrolimus 44Etoposide 43Antilymphocyte Serum 41Melphalan 37Methotrexate 31fludarabine 30Bortezomib 30Prednisone 28Bendamustine Hydrochloride 28Cytarabine 24Cord Blood Stem Cell Transplantation 23obinutuzumab 22Vincristine 22Methylprednisolone 21Flow Cytometry 21ibrutinib 19venetoclax 18sargramostim 17Granulocyte Colony-Stimulating Factor 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × marizomib × Clear all
NCT00396864 2017-11-22

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Celgene

Phase 1 Completed
51 enrolled
DermatologicLymphoid

Lymphoma, Neoplasms, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT00629473 2017-11-22

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Celgene

Phase 1 Completed
86 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡